SELLAS Life Sciences Group, Inc. (SLS)
SLS moved a median of -0.63% 30 minutes after news, and 0.00% by the close. How SLS actually reacts to news — the realized, point-in-time move the market made, measured across 257 labeled events over the last three years with zero look-ahead.
SLS’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.21% | 42% | 255 |
| 30-min | -0.63% | 42% | 255 |
| 60-min | -0.90% | 42% | 255 |
| to close | 0.00% | 48% | 251 |
| Middle 50% of SLS reactions | -2.47% to +1.66% |
|---|---|
| Median reaction (30-min) | -0.63% |
| Measured reactions | 257 |
Half of all SELLAS Life Sciences Group, Inc. news events land between -2.47% and +1.66% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when SLS moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to SLS's baseline. Nothing else.
Recent SLS events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| SELLAS Life Sciences Presents Preclinical Data Demonstrating SLS009 Activity in Pancreatic Cancer Models at the 2026 AACR Conference on Pancreatic Cancer | Press release | GlobeNewswire | -0.17% | -1.44% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against SELLAS Life Sciences Group, Inc. (SLS) and Encourages Shareholders to Learn More About the Investigation | Press release | ACCESS Newswire | +0.19% | +1.66% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages SELLAS Life Sciences Group, Inc. (SLS) Shareholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | -0.21% | -3.86% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages SELLAS Life Sciences Group, Inc. (SLS) Stockholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | -0.04% | -8.41% | |
| SELLAS Life Sciences Group, Inc. (SLS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | -0.20% | -1.82% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages SELLAS Life Sciences Group, Inc. (SLS) Stockholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | +0.36% | +2.05% | |
| SELLAS Life Sciences Group, Inc. (SLS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | +0.36% | +2.05% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against SELLAS Life Sciences Group, Inc. (SLS) and Encourages Stockholders to Learn More About the Investigation | Press release | ACCESS Newswire | -0.35% | -1.70% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages SELLAS Life Sciences Group, Inc. (SLS) Investors to Inquire about Securities Investigation | Press release | ACCESS Newswire | -0.36% | -2.28% | |
| SELLAS Life Sciences to Present Preclinical Data on SLS009 in Pancreatic Ductal Adenocarcinoma at the 2026 AACR Conference on Pancreatic Cancer | Press release | GlobeNewswire | +0.93% | +6.71% | |
| Form 10-Q SELLAS Life Sciences For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.67% | -1.26% | |
| Form 8-K SELLAS Life Sciences For: Aug 11 | SEC filing · Form 8-K | SEC EDGAR | +0.67% | -1.26% | |
| SELLAS Life Sciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | +0.67% | -1.26% | |
| Form 8-K SELLAS Life Sciences For: Jul 24 | SEC filing · Form 8-K | SEC EDGAR | -3.10% | -2.13% | |
| Form 8-K SELLAS Life Sciences For: Jun 24 | SEC filing · Form 8-K | SEC EDGAR | -0.76% | +14.33% | |
| Form 8-K SELLAS Life Sciences For: Jun 16 | SEC filing · Form 8-K | SEC EDGAR | +3.09% | +1.43% | |
| Form S-8 SELLAS Life Sciences | SEC filing · Form S-8 | SEC EDGAR | -0.33% | +2.24% | |
| Form 8-K SELLAS Life Sciences For: Jun 02 | SEC filing · Form 8-K | SEC EDGAR | -5.67% | -7.44% | |
| SELLAS Life Sciences to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | +3.54% | +14.15% | |
| Form 10-Q SELLAS Life Sciences For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -2.14% | +3.65% | |
| Form 8-K SELLAS Life Sciences For: May 12 | SEC filing · Form 8-K | SEC EDGAR | -2.14% | +3.65% | |
| SELLAS Life Sciences Reports First Quarter 2026 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | -2.14% | +3.65% | |
| Form ARS SELLAS Life Sciences For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -1.58% | +0.45% | |
| Form DEF 14A SELLAS Life Sciences For: Jun 16 | SEC filing · Form DEF | SEC EDGAR | -1.58% | +0.45% | |
| Form DEFA14A SELLAS Life Sciences | SEC filing · Form DEFA14A | SEC EDGAR | -1.58% | +0.45% | |
| Form S-3ASR SELLAS Life Sciences | SEC filing · Form S-3ASR | SEC EDGAR | +4.24% | +13.22% | |
| Form 10-K SELLAS Life Sciences For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -12.14% | -15.00% | |
| Form 8-K SELLAS Life Sciences For: Mar 19 | SEC filing · Form 8-K | SEC EDGAR | -12.14% | -15.00% | |
| SELLAS Life Sciences Reports Full Year 2025 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | -12.14% | -15.00% | |
| SELLAS Life Sciences to Present Preclinical Data Highlighting Potent Activity of SLS009 in AML at the 2026 AACR Conference | Press release | GlobeNewswire | +1.40% | -1.20% | |
| SELLAS Life Sciences Announces Enrollment of First Patient in Newly Diagnosed First-Line AML Trial of SLS009 | Press release | GlobeNewswire | -0.72% | -8.88% | |
| Form 8-K SELLAS Life Sciences For: Mar 11 | SEC filing · Form 8-K | SEC EDGAR | -0.72% | -8.88% | |
| SELLAS Life Sciences Enters Agreement with IMPACT-AML to Expand SLS009 Clinical Program into Europe | Press release | GlobeNewswire | -0.87% | +0.00% | |
| Form 8-K SELLAS Life Sciences For: Jan 07 | SEC filing · Form 8-K | SEC EDGAR | -2.94% | -5.39% | |
| SELLAS Life Sciences Provides Update on Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) | Press release | GlobeNewswire | -0.37% | +23.16% | |
| SELLAS Life Sciences Presents Positive Phase 2 Data of SLS009 in Combination with AZA/VEN in Relapsed/Refractory AML-MR at ASH 2025 | Press release | GlobeNewswire | +0.80% | -2.67% | |
| Form EFFECT SELLAS Life Sciences | SEC filing · Form EFFECT | SEC EDGAR | +0.34% | +0.69% | |
| Form 10-Q SELLAS Life Sciences For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +3.00% | — | |
| Form 8-K SELLAS Life Sciences For: Nov 12 | SEC filing · Form 8-K | SEC EDGAR | +3.00% | — | |
| SELLAS Life Sciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | +3.00% | — | |
| SELLAS Life Sciences Announces Presentation of Phase 2 Data of SLS009 in Combination with Azacitidine and Venetoclax in Relapsed/Refractory AML with MDS-Related Changes (AML-MR) at the 2025 American Society of Hematology (ASH) Annual Meeting | Press release | GlobeNewswire | -0.81% | -2.72% | |
| Form 8-K SELLAS Life Sciences For: Oct 24 | SEC filing · Form 8-K | SEC EDGAR | +0.51% | -1.02% | |
| SELLAS Life Sciences Group Announces Exercise of Existing Warrants Held by a Current Institutional Investor for $31 Million in Gross Proceeds | Press release | GlobeNewswire | +0.51% | -1.02% | |
| SELLAS Life Sciences to Participate in the J.P. Morgan U.S. Opportunities Forum | Press release | GlobeNewswire | -0.38% | +3.17% | |
| SELLAS Life Sciences to Present In Vivo Preclinical Data Demonstrating Statistically Significant Survival Benefit of SLS009 in T-Cell Prolymphocytic Leukemia at the European Society for Medical Oncology (ESMO) Congress 2025 | Press release | GlobeNewswire | -1.76% | +0.50% | |
| Form S-3 SELLAS Life Sciences | SEC filing · Form S-3 | SEC EDGAR | -1.76% | +0.50% | |
| Form 8-K SELLAS Life Sciences For: Oct 01 | SEC filing · Form 8-K | SEC EDGAR | -3.67% | -1.05% | |
| SELLAS Life Sciences Group to Host Virtual R&D Day on October 29, 2025: Advancing Novel Therapies in Acute Myeloid Leukemia (AML): An Overview of the Ongoing Phase 3 REGAL Trial of Galinpepimut-S (GPS) and SLS009 Program Update | Press release | GlobeNewswire | +1.60% | +3.21% | |
| Form 8-K SELLAS Life Sciences For: Sep 10 | SEC filing · Form 8-K | SEC EDGAR | +2.24% | +6.18% | |
| SELLAS Life Sciences Group Announces Exercise of Existing Warrants Held by a Current Institutional Investor for $23.6 Million in Gross Proceeds | Press release | GlobeNewswire | +2.24% | +6.18% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the SLS section they belong to.
Where else SLS is measured.
SLS earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Enanta Pharmaceuticals, Inc. (ENTA) | 257 | +0.06% | 50% |
| FORTY SEVEN (FTSV) | 257 | +0.01% | 51% |
| Addus HomeCare Corporation (ADUS) | 256 | -0.02% | 47% |
| Celldex Therapeutics, Inc. (CLDX) | 256 | +0.04% | 57% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is SELLAS Life Sciences Group, Inc.'s median reaction calculated?
Every labeled SLS news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 257 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 42% of SLS's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does SLS's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.